Sangamo Therapeutics (SGMO) to Post Earnings on Thursday

Sangamo Therapeutics (NASDAQ:SGMO) is expected to post its Q2 2026 resultson Thursday, August 6th. Analysts expect Sangamo Therapeutics to announce earnings of ($0.04) per share and revenue of $14.6670 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $0.07 on Tuesday. The stock has a 50-day moving average of $0.12 and a 200-day moving average of $0.25. The company has a market cap of $30.66 million, a PE ratio of -0.17 and a beta of 1.30. Sangamo Therapeutics has a one year low of $0.06 and a one year high of $0.77.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, April 16th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Sangamo Therapeutics has an average rating of “Reduce” and an average price target of $5.50.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SGMO. Cetera Investment Advisers acquired a new stake in shares of Sangamo Therapeutics in the 4th quarter worth about $31,000. XTX Topco Ltd bought a new position in shares of Sangamo Therapeutics in the second quarter valued at approximately $41,000. State of Wyoming bought a new position in shares of Sangamo Therapeutics in the fourth quarter valued at approximately $47,000. Engineers Gate Manager LP boosted its position in shares of Sangamo Therapeutics by 101.7% during the second quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 44,078 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in Sangamo Therapeutics during the 4th quarter worth $56,000. 56.92% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.